ssmhealth.com
Cure8 news brief
Why This Matters
Many people with IBD use over-the-counter pain relievers without realizing they can irritate the gut. This article explains when ibuprofen or naproxen might raise risks for people with Crohn’s disease or ulcerative colitis, and offers safer pain-management options.
Who Should Pay Attention
Adults with Crohn’s disease or ulcerative colitis, caregivers, and gastroenterology clinicians involved in pain management decisions.
Study Snapshot
Story typePatient Advocacy
Evidence typePatient Education
Source depthFull source text
What To Know
SSM Health’s gastroenterology expert summarizes that NSAIDs reduce prostaglandins that help protect the gut lining, so long-term or frequent use may raise the risk of IBD flare or other gastrointestinal complications. Short, occasional courses may be reasonable in people whose disease is in deep remission, but routine or daily use is discouraged.
The article emphasizes practical precautions if NSAIDs are needed: use the lowest effective dose for the shortest time, monitor closely for signs of worsening (increased diarrhea, rectal bleeding, new/worse abdominal pain), and stay in touch with your gastroenterologist.
It also encourages identifying the cause of pain (which is not always active inflammation) and considering alternatives such as acetaminophen, targeted therapies, physical therapy, topical treatments, behavioral approaches, or specialist referral.
The piece cautions against long-term opioid use and notes that individual sensitivity to NSAIDs varies; recommendations should be individualized based on disease activity and prior responses.
Keep In Mind
The article is a clinician-reviewed patient-education piece from SSM Health summarizing current clinical caution about NSAIDs; it is not a systematic review or new clinical trial. Advice is general — individual decisions should be made with your gastroenterologist, especially if disease has been recently active.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationssmhealth.com
Indexed viaGoogle News
Source typeWeb article
PublishedOct 2, 2026, 11:56 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Eli Lilly shares two-year results for Omvoh in active Crohn’s disease patients
Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...
J&J's Stelara granted EC approval to treat Crohn's disease in paediatric patients - PMLiVE
This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.
Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease
A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based...